Apr. 20 at 11:21 PM
$INVA $ARMP Innoviva (through its subsidiary Innoviva Strategic Opportunities LLC) beneficially owns approximately 55.47 million shares of Armata Pharmaceuticals (ARMP) on a fully diluted/as-converted and as-exercised basis, representing about 83.1–83.3% of Armata’s common stock. http://stocktitan.net
This includes:
• Direct/common shares owned: 25,076,769 shares (roughly 68–69% of currently outstanding shares). http://wallstreetzen.com
• Additional shares from warrants (about 10.65 million) and a convertible loan (about 19.74 million shares upon conversion, excluding accrued interest). http://sec.gov
Armata has approximately 36.2–36.6 million shares outstanding as of early 2026 (e.g., ~36.23 million in recent reports and ~36.6 million as of March 2026). http://finance.yahoo.com
This ownership stems from multiple investments since 2020 (initial ~
$25M deal, followed by
$45M in 2022, and later credit facilities/loans that are partially convertible), with Innoviva as Armata’s largest/majority shareholder
